Skip to main content
    S

    Sensei Biotherapeutics Inc (SNSE)

    Official site

    BIOTECHNOLOGY

    $13.85
    +0.85 (+6.54%)

    Last updated: Jun 15, 2026 at 5:00 PM ET

    Sensei Biotherapeutics Inc (SNSE) Financials: Revenue, Profit and Cash Flow

    Updated May 15, 2026. Financial statements from company filings, amounts in US dollars.

    Sensei Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$21.09M, operating cash flow was -$20.45M and free cash flow was -$20.47M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$170.24M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $22.29M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenueN/A$551.00K$571.00K$1.81M$685.00K$209.00K$73.00K$44.00K
    Gross profitN/A-$551.00K-$571.00K-$1.81M-$685.00K-$209.00K-$73.00K-$44.00K
    Research and development$10.96M$18.63M$18.30M$30.38M$21.66M$11.92M$8.35M$8.23M
    Operating income-$22.29M-$31.66M-$37.06M-$50.19M-$37.48M-$19.45M-$12.44M-$12.74M
    Net income-$21.09M-$30.16M-$34.10M-$48.81M-$36.79M-$20.10M-$16.74M-$13.04M
    EBITDA-$20.91M-$29.52M-$33.39M-$48.84M-$35.44M-$18.20MN/A-$12.70M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$0$0-$4.85M$0$0$544.00K$0$0$0$2.85M$0$0
    Gross profit-$132.96M$67.00KN/A-$37.00K-$30.00K-$139.00K-$140.00K-$135.00K-$137.00K-$135.00K-$455.00K-$491.00K
    Operating income-$170.63M-$4.96M-$4.85M-$5.21M-$7.27M-$7.32M-$7.82M-$7.79M-$8.73M-$8.14M-$7.74M-$10.19M
    Net income-$170.24M-$4.72M-$4.57M-$4.94M-$6.86M-$7.77M-$7.25M-$7.14M-$7.99M-$7.41M-$7.12M-$9.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.45M by $7.22M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$22.90M$45.36M$74.37M$118.38M$153.22M$21.43M$1.22M$1.85M
    Current assets$21.51M$41.93M$67.25M$108.59M$148.54M$20.08M$502.00K$1.28M
    Cash and equivalents$8.67M$9.99M$13.01M$17.80M$7.16M$16.60M$251.00K$653.00K
    Total liabilities$4.31M$6.97M$9.48M$14.97M$6.71M$5.54M$69.88M$55.33M
    Short-term debt$1.45M$2.32M$2.44M$2.13M$680.00K$32.00K$16.05M$696.00K
    Long-term debtN/AN/AN/AN/AN/A$567.00KN/A$4.05M
    Shareholder equity$18.59M$38.39M$64.89M$103.41M$146.51M$15.89M-$68.66M-$53.48M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$205.38M$22.90M$27.59M$31.78M$38.27M$45.36M$53.25M$59.80M$66.69M$74.37M$81.66M$89.58M
    Total liabilities$14.19M$4.31M$4.58M$4.47M$6.29M$6.97M$7.47M$7.61M$8.22M$9.48M$10.66M$10.38M
    Cash and equivalents$152.32M$8.67M$10.56M$12.56M$9.88M$9.99M$19.13M$11.89M$10.96M$13.01M$11.34M$10.23M
    Shareholder equity$191.19M$18.59M$23.01M$27.31M$31.99M$38.39M$45.78M$52.19M$58.47M$64.89M$71.00M$79.20M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$20.45M-$24.67M-$32.02M-$39.03M-$30.26M-$17.70M-$8.57M-$10.31M
    Capital expenditures$16.00K$146.00K$180.00K$321.00K$2.03M$1.21M$53.00K$31.00K
    Free cash flow-$20.47M-$24.82M-$32.20M-$39.35M-$32.28M-$18.91M-$8.62M-$10.34M
    Investing cash flow$19.77M$22.44M$38.41M$49.95M-$143.12M-$1.40M-$53.00K-$31.00K
    Financing cash flow-$645.00K-$787.00K-$11.17M-$287.00K$163.94M$35.45M$8.22M$750.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$10.73M-$3.86M-$3.59M-$5.91M-$7.09M-$5.79M-$5.47M-$5.79M-$7.62M-$6.16M-$4.66M-$9.46M
    Capital expenditures$6.00K$0$0$16.00K$0$0$0$109.00K$37.00K$0$0$29.00K
    Free cash flow-$10.74M-$3.86M-$3.59M-$5.92M-$7.09M-$5.79M-$5.47M-$5.90M-$7.65M-$6.16M-$4.66M-$9.49M
    Last 12 quarters

    Frequently Asked Questions About SNSE

    What is Sensei Biotherapeutics' annual revenue?

    Sensei Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Sensei Biotherapeutics profitable?

    No. Sensei Biotherapeutics reported net income of -$21.09M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SNSE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$20.45M minus capital expenditures of $16.00K produced free cash flow of -$20.47M.

    How much debt does Sensei Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.45M and cash and equivalents of $8.67M.